Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.

Inflammatory Bowel Disease III: Crohn's Disease

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Microbiota Therapy: Ready for Clinical Practice?

Visceral medicine·2024

Same author

Childlessness in Patients with Inflammatory Bowel Disease - Data from the Prospective Multi-center Swiss IBD Cohort Study.

Journal of gastrointestinal and liver diseases : JGLD·2023

Same author

Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.

Journal of Crohn's & colitis·2023

Same author

Concomitant 5-aminosalicylic acid treatment does not affect 6-thioguanine nucleotide levels in patients with inflammatory bowel disease on thiopurines.

Annals of gastroenterology·2023

Same author

[Microbiome: from pathophysiology to clinical application?]

Deutsche medizinische Wochenschrift (1946)·2023

Same author

Crosstalk within peripheral blood mononuclear cells mediates anti-inflammatory effects of n-3 PUFA-rich lipid emulsions in parenteral nutrition.

Clinical nutrition (Edinburgh, Scotland)·2023

Search research articles

Related Experiment Video

Updated: May 14, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Recent advances using immunomodulators for inflammatory bowel disease.

Ole Haagen Nielsen¹, Jacob Tveiten Bjerrum, Hans Herfarth

¹Department of Gastroenterology, Medical Section, Herlev Hospital, University of Copenhagen, Denmark. ohn@dadlnet.dk

Journal of Clinical Pharmacology

|February 15, 2013

Summary

This summary is machine-generated.

Optimizing immunomodulator therapy with azathioprine, 6-mercaptopurine, and methotrexate (MTX) for inflammatory bowel disease (IBD) is crucial. This review focuses on pharmacogenetics, pharmacokinetics, and adverse events to refine treatment regimens for IBD patients.

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Related Experiment Videos

Last Updated: May 14, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

Area of Science:

Gastroenterology
Clinical Pharmacology
Immunology

Background:

Thiopurines and methotrexate (MTX) are standard treatments for inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis (UC).
Current treatment regimens for azathioprine (AZA), 6-mercaptopurine (6-MP), and MTX require optimization due to varying patient responses and potential side effects.
Recent studies highlight the need for a more rational approach to immunomodulator use in IBD management.

Purpose of the Study:

To review and update the optimal use of immunomodulators (AZA, 6-MP, MTX) in IBD treatment.
To identify patient subgroups who benefit most from immunomodulator therapy, including combination with biologics.
To discuss the role of pharmacogenetics, pharmacokinetics, and therapeutic drug monitoring in optimizing immunomodulator efficacy and safety.

Main Methods:

Review of recent studies on immunomodulator use in IBD.
Analysis of pharmacokinetic and pharmacogenetic data for AZA, 6-MP, and MTX.
Evaluation of adverse event profiles and cancer risk associated with immunomodulator therapy.
Discussion of therapeutic blood level monitoring and treatment discontinuation strategies.

Main Results:

Thiopurines may have a preventive effect against colorectal cancer in IBD patients.
Optimizing immunomodulator therapy requires consideration of individual patient factors, including genetics and drug metabolism.
Careful patient selection and monitoring are essential to minimize severe side effects and maximize therapeutic benefits.

Conclusions:

A personalized approach integrating pharmacokinetics, pharmacogenetics, and therapeutic drug monitoring is needed for rational immunomodulator use in IBD.
Further research is warranted to refine treatment protocols and improve outcomes for IBD patients on thiopurines and MTX.
Appropriate management, including considering discontinuation, is vital for long-term IBD care.